Translations:GLP-1 receptor agonist/10/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 21:59, 5 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (GLP-1 receptor agonist)
===Non-alcoholic fatty liver disease===
GLP-1 agonists are being studied for the treatment of [[non-alcoholic fatty liver disease]] (NAFLD). They are at least as effective as the medications in current use, [[pioglitazone]] and [[Vitamin E]], and significantly reduce steatosis, ballooning necrosis, lobular inflammation, and fibrosis according to a 2023 systematic review. Semaglutide is in a Phase III study for [[non-alcoholic steatohepatitis]], the more severe form of NAFLD, as of 2023.

Non-alcoholic fatty liver disease

GLP-1 agonists are being studied for the treatment of non-alcoholic fatty liver disease (NAFLD). They are at least as effective as the medications in current use, pioglitazone and Vitamin E, and significantly reduce steatosis, ballooning necrosis, lobular inflammation, and fibrosis according to a 2023 systematic review. Semaglutide is in a Phase III study for non-alcoholic steatohepatitis, the more severe form of NAFLD, as of 2023.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:GLP-1_receptor_agonist/10/en&oldid=110960"